Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 4/20 | 0.52 |
| ▸ | PAK4 | O96013 | 3/20 | 0.52 |
| ▸ | TYRO3 | Q06418 | 9/20 | 0.45 |
| ▸ | SELP | P16109 | 1/20 | 0.45 |
| ▸ | MERTK | Q12866 | 7/20 | 0.45 |
| ▸ | AXL | P30530 | 6/20 | 0.44 |
| ▸ | IGF1R | P08069 | 3/20 | 0.43 |
| ▸ | CTSC | P53634 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 2/20 | 0.41 |
| ▸ | GAS6 | Q14393 | 2/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20154970 | 0.85 | AXL (0.52) | PAK4TYRO3SELPMERTKAXL | |
| SCHEMBL20154904 | 0.81 | PLK4 (0.52) | PLK4PAK4TYRO3SELPMERTK | |
| SCHEMBL20155307 | 0.79 | TYRO3 (0.63) | PLK4PAK4TYRO3MERTKAXL | |
| SCHEMBL21299961 | 0.73 | PLK4 (0.50) | PLK4PAK4TYRO3SELPMERTK | |
| SCHEMBL30373488 | 0.72 | PAK4 (0.67) | PLK4PAK4IGF1R | |
| SCHEMBL30373439 | 0.72 | PAK4 (0.61) | PLK4PAK4TYRO3IGF1RSYK | |
| SCHEMBL20154911 | 0.67 | TYRO3 (0.54) | PAK4TYRO3SELPMERTKAXL | |
| SCHEMBL23889462 | 0.65 | PAK4 (0.66) | PLK4PAK4 | |
| SCHEMBL13022269 | 0.65 | CDK1 (0.52) | SYK | |
| SCHEMBL17999849 | 0.65 | NTRK1 (0.46) | PLK4PAK4IGF1RCTSCFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3530656-B1 | 2-SUBSTITUTED AROMATIC RING-PYRIMIDINE DERIVATIVE, AND PREPARATION AND APPLICATION THEREOF | UNIV ZHEJIANG (CN) | 2022-01-05 | — | — | EP | disclosed |
| US-10822327-B2 | 2-substituted aromatic ring-pyrimidine derivative and preparation and application thereof | ZHEJIANG UNIVERSITY (CN) | 2020-11-03 | — | — | US | disclosed |
| EP-3530656-A1 | 2-SUBSTITUTED AROMATIC RING-PYRIMIDINE DERIVATIVE, AND PREPARATION AND APPLICATION THEREOF | Zhejiang University (CN) | 2019-08-28 | — | — | EP | disclosed |
| WO-2018086547-A1 | 2-SUBSTITUTED AROMATIC RING-PYRIMIDINE DERIVATIVE, AND PREPARATION AND APPLICATION THEREOF | 浙江大学 | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10822327-B2 | 2-substituted aromatic ring-pyrimidine derivative and preparation and application thereof | CHEK1, CHEK2, PLK1 | PLK4 34/4885PAK4 131/4885TYRO3 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.